USAntibiotics, the sole licensed American maker of penicillin-based Amoxicillin and Amoxil Clavulanate, the popular antibiotics commonly known as Amoxil® and Augmentin®, today reopened its Bristol, Tenn. manufacturing facility, which had slipped into bankruptcy and ceased operations last year. The event marks the first time the facility is under American ownership.
When the 360,000-square foot facility comes online, it will have the capacity to produce 300 million capsules and two billion tablets annually and can manufacture and stockpile a five-year supply of Amoxicillin for the United States.
Thirty percent of all antibiotics prescribed in the United States each year are Amoxicillin. Upon reopening, USAntibiotics will be the only American company able to manufacture this life saving antibiotic. At full capacity, the facility in Bristol, TN will be able to meet 100 percent of the nation's demand for Amoxicillin. Every dose of Amoxicillin that will be needed in the United States over the next five years can be manufactured and stored at the USAntibiotics facility, supplying the entire U.S. strategic stockpile. This shift is a complete reversal of the current situation where every dose is sourced from outside the USA.
"As the first doses of USAntibiotics' life-saving drugs move down the assembly line, America will have declared its independence from Chinese antibiotics," said Rick Jackson, founder, CEO, and chairman of Jackson Healthcare, which purchased the Bristol facility from bankruptcy earlier this year. "Our mission is to solve our nation's reliance on foreign Amoxicillin and create a secure stockpile that will stand the test of time. Beginning today, the United States is back in the business of essential medicines."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!